Company Overview of Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding ...
300 Third Street
Cambridge, MA 02142
Founded in 2002
Key Executives for Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. does not have any Key Executives recorded.
Alnylam Pharmaceuticals, Inc. Key Developments
Alnylam Pharmaceuticals, Inc Appoints Colleen Reitan to the Board of Directors, Effective June 1, 2018
May 15 18
Alnylam Pharmaceuticals, Inc. announced the appointment of Colleen Reitan, to Alnylam’s Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of Health Care Service Corporation (HCSC). Prior to her role as President of Operations at HCSC, she served as the company’s Chief Operating Officer. Previously, Ms. Reitan served as President and Chief Operating Officer of Blue Cross Blue Shield of Minnesota, and as a director on the boards of Prime Therapeutics, Availity, Federal Employee Board of Managers, and MEDecision.
Alnylam Pharmaceuticals, Inc. Presents at TIDES 2018: Oligonucleotide and Peptide Therapeutics, May-07-2018 through May-10-2018
May 4 18
Alnylam Pharmaceuticals, Inc. Presents at TIDES 2018: Oligonucleotide and Peptide Therapeutics, May-07-2018 through May-10-2018. Venue: Hynes Convention Center, Boston, Massachusetts, United States. Presentation Date & Speakers: May-07-2018, Lubomir Nechev, Vice President of Process Sciences. May-08-2018, John M. Maraganore, CEO & Executive Director, Muthiah Manoharan, Senior VP of Drug Discovery & Member of Scientific Advisory Board. May-09-2018, Mark K. Schlegel, Senior Scientist, RNAi Discovery, Patrick Haslett, Executive Director of Clinical Research, Paul Peng, Principal Scientist, Process Sciences. May-10-2018, Bo Pang, Associate Director, Analytical Development, Kallanthottathil G. Rajeev, Senior Director, Chemistry.
Alnylam Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2018; Expects to Gain Regulatory Approval for Patisiran from the FDA in Mid-2018
May 3 18
Alnylam Pharmaceuticals, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2018. The net loss according to accounting principles generally accepted in the U.S. (GAAP) was $141.2 million or $1.41 per share on both a basic and diluted basis as compared to a net loss of $107.3 million or $1.25 per share on both a basic and diluted basis for the same period in the previous year. The non-GAAP net loss was $121.6 million or $1.22 per share on both a basic and diluted basis as compared to a non-GAAP net loss of $91.6 million, or $1.06 per share on both a basic and diluted basis for the same period in the previous year. Revenues were $21.9 million as compared to $19.0 million in the first quarter of 2017. Revenues included $18.9 million from the company's alliance with Sanofi Genzyme. Loss from operations was $147,405,000 against $106,511,000 a year ago. Loss before income taxes was $141,276,000 against $107,290,000 a year ago.
The company expects to gain regulatory approval for patisiran from the FDA in mid-2018. The FDA has set an action date of August 11, 2018, under the Prescription Drug User Fee Act (PDUFA). The company expects to launch patisiran in the U.S. shortly after FDA approval. The company plans to file for regulatory approval for patisiran in Japan and other global markets, including a Japanese NDA filing with the Pharmaceuticals and Medical Device Agency (PMDA) in mid-2018. The company intends to report topline interim results from the ENVISION Phase 3 trial for givosiran in the September timeframe. Alnylam intends to initiate the lumasiran Phase 3 study in mid-2018. The Medicines Company has guided its intention to initiate enrollment in the ORION-4 cardiovascular outcomes (CVOT) study in mid-2018. Alnylam and Sanofi expect to enroll patients in the ATLAS Phase 3 program of fitusiran in patients with hemophilia A and B with or without inhibitors throughout the year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|